HRP20210245T1 - Primjena fk506 za liječenje plućne arterijske hipertenzije - Google Patents
Primjena fk506 za liječenje plućne arterijske hipertenzije Download PDFInfo
- Publication number
- HRP20210245T1 HRP20210245T1 HRP20210245TT HRP20210245T HRP20210245T1 HR P20210245 T1 HRP20210245 T1 HR P20210245T1 HR P20210245T T HRP20210245T T HR P20210245TT HR P20210245 T HRP20210245 T HR P20210245T HR P20210245 T1 HRP20210245 T1 HR P20210245T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- arterial hypertension
- pulmonary arterial
- use according
- subject
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161481317P | 2011-05-02 | 2011-05-02 | |
| PCT/US2012/035793 WO2012151153A1 (en) | 2011-05-02 | 2012-04-30 | Use of fk506 for the treatment of pulmonary arterial hypertension |
| EP12779354.5A EP2704711B1 (en) | 2011-05-02 | 2012-04-30 | Use of fk506 for the treatment of pulmonary arterial hypertension |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210245T1 true HRP20210245T1 (hr) | 2021-04-02 |
Family
ID=47108011
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210245TT HRP20210245T1 (hr) | 2011-05-02 | 2012-04-30 | Primjena fk506 za liječenje plućne arterijske hipertenzije |
Country Status (19)
| Country | Link |
|---|---|
| US (6) | US9474745B2 (enExample) |
| EP (3) | EP3821891B1 (enExample) |
| JP (1) | JP6177765B2 (enExample) |
| AU (2) | AU2012250974B9 (enExample) |
| CA (1) | CA2834368C (enExample) |
| CY (1) | CY1123900T1 (enExample) |
| DK (2) | DK2704711T3 (enExample) |
| ES (2) | ES2856173T3 (enExample) |
| FI (1) | FI3821891T3 (enExample) |
| HR (1) | HRP20210245T1 (enExample) |
| HU (1) | HUE053229T2 (enExample) |
| LT (1) | LT2704711T (enExample) |
| PL (1) | PL2704711T3 (enExample) |
| PT (2) | PT2704711T (enExample) |
| RS (1) | RS61480B1 (enExample) |
| SI (1) | SI2704711T1 (enExample) |
| SM (1) | SMT202100085T1 (enExample) |
| WO (1) | WO2012151153A1 (enExample) |
| ZA (1) | ZA201307905B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2017009110A (es) * | 2015-01-13 | 2017-11-09 | Vivus Inc | Terapia de combinacion para hipertension pulmonar. |
| EP3294294A4 (en) * | 2015-05-08 | 2019-01-02 | Vivus, Inc. | Compositions and methods for the treatment or prevention of pulmonary hypertension |
| CN105062976B (zh) * | 2015-08-05 | 2018-05-11 | 中国医学科学院基础医学研究所 | 肺动脉高压治疗药物的干细胞筛选模型及应用 |
| ES2683921B1 (es) * | 2017-03-28 | 2019-04-22 | Univ Vigo | Método para la determinación del pronóstico en sujetos diagnosticados con hipertensión arterial pulmonar |
| JP2020520906A (ja) * | 2017-05-19 | 2020-07-16 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 肺高血圧症の治療のためのエンザスタウリン及び脆弱性ヒスチジン三連構造（ｆｈｉｔ）増加剤 |
| EP3773571A1 (en) * | 2018-03-28 | 2021-02-17 | Georg-August-Universitaet Goettingen Stiftung Oeffentlichen Rechts, Universitaetsmedizin | Prevention or treatment of chronic organ injury |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6489335B2 (en) * | 2000-02-18 | 2002-12-03 | Gholam A. Peyman | Treatment of ocular disease |
| US20050119330A1 (en) * | 2003-03-17 | 2005-06-02 | Kao Peter N. | Use of antiproliferative agents in the treatment and prevention of pulmonary proliferative vascular diseases |
| US8222271B2 (en) | 2006-03-23 | 2012-07-17 | Santen Pharmaceutical Co., Ltd. | Formulations and methods for vascular permeability-related diseases or conditions |
| FR2936060B1 (fr) * | 2008-09-17 | 2010-11-19 | Assist Publ Hopitaux De Paris | Procede de diagnostic d'une sclerodermie systemique ou d'une hypertension arterielle pulmonaire. |
| MX2011004284A (es) * | 2008-10-22 | 2011-06-21 | Sam Amer & Co Inc | Metodo para tratar la hipertension arterial pulmonar. |
-
2012
- 2012-04-30 JP JP2014509338A patent/JP6177765B2/ja active Active
- 2012-04-30 PL PL12779354T patent/PL2704711T3/pl unknown
- 2012-04-30 EP EP20211109.2A patent/EP3821891B1/en active Active
- 2012-04-30 HR HRP20210245TT patent/HRP20210245T1/hr unknown
- 2012-04-30 DK DK12779354.5T patent/DK2704711T3/da active
- 2012-04-30 ES ES12779354T patent/ES2856173T3/es active Active
- 2012-04-30 CA CA2834368A patent/CA2834368C/en active Active
- 2012-04-30 DK DK20211109.2T patent/DK3821891T3/da active
- 2012-04-30 LT LTEP12779354.5T patent/LT2704711T/lt unknown
- 2012-04-30 RS RS20210239A patent/RS61480B1/sr unknown
- 2012-04-30 PT PT127793545T patent/PT2704711T/pt unknown
- 2012-04-30 SI SI201231881T patent/SI2704711T1/sl unknown
- 2012-04-30 HU HUE12779354A patent/HUE053229T2/hu unknown
- 2012-04-30 FI FIEP20211109.2T patent/FI3821891T3/fi active
- 2012-04-30 EP EP12779354.5A patent/EP2704711B1/en active Active
- 2012-04-30 PT PT202111092T patent/PT3821891T/pt unknown
- 2012-04-30 SM SM20210085T patent/SMT202100085T1/it unknown
- 2012-04-30 ES ES20211109T patent/ES2954905T3/es active Active
- 2012-04-30 US US14/113,375 patent/US9474745B2/en active Active
- 2012-04-30 EP EP23177834.1A patent/EP4279130A3/en not_active Withdrawn
- 2012-04-30 AU AU2012250974A patent/AU2012250974B9/en active Active
- 2012-04-30 WO PCT/US2012/035793 patent/WO2012151153A1/en not_active Ceased
-
2013
- 2013-10-23 ZA ZA2013/07905A patent/ZA201307905B/en unknown
-
2016
- 2016-09-21 US US15/271,794 patent/US20170007585A1/en not_active Abandoned
-
2017
- 2017-08-03 AU AU2017210583A patent/AU2017210583B2/en active Active
- 2017-10-12 US US15/782,153 patent/US20180185340A1/en not_active Abandoned
-
2018
- 2018-11-21 US US16/198,242 patent/US20190091208A1/en not_active Abandoned
-
2020
- 2020-07-29 US US16/941,778 patent/US20220184042A1/en not_active Abandoned
-
2021
- 2021-02-23 CY CY20211100151T patent/CY1123900T1/el unknown
-
2023
- 2023-01-06 US US18/151,028 patent/US20230404982A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210245T1 (hr) | Primjena fk506 za liječenje plućne arterijske hipertenzije | |
| CY1120832T1 (el) | Τροποποιητες πυρηνικης μεταφορας και χρησεις αυτων | |
| CY1120049T1 (el) | (2s)-ν-[(1s)-1-κυανο-2-φαινυλαιθυλ]-1,4-οξαζεπαν-2-καρβοξαμιδια ως αναστολεις της διπεπτιδυλικης πεπτιδασης i | |
| ME02895B (me) | Derivati betulina | |
| EA201491339A1 (ru) | Замещенные аннеллированные пиримидины и триазины и их применение | |
| EA201400119A1 (ru) | Фармацевтическая композиция, способы лечения и их применение | |
| ME02910B (me) | Spojevi tetrahidropirolotiazina | |
| EA201490540A1 (ru) | Соединения и композиции в качестве ингибиторов с-kit киназы | |
| GT201300243A (es) | Derivados de ácido 3-fenilpropiónico ramificados y su uso | |
| EA201291410A1 (ru) | Фармацевтические композиции, содержащие 4-амино-5-фтор-3-[6-(4-метилпиперазин-1-ил)-1h-бензимидазол-2-ил]-1h-хинолин-2-она лактат моногидрат | |
| WO2014004993A3 (en) | Methods of reducing ldl-p | |
| EA201490254A1 (ru) | Комбинированное лечение гепатита с | |
| EA201590251A1 (ru) | Новые 5-аминотетрагидрохинолин-2-карбоновые кислоты и их применение | |
| HRP20170848T1 (hr) | Kompozicije i metode za liječenje pluće hipertenzije | |
| WO2012094598A3 (en) | Pharmaceutical compositions of iron for oral administration | |
| EA201490378A1 (ru) | ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β | |
| EA201490552A1 (ru) | Холиновая соль замещенного циклобутендиона, обладающая противовоспалительной способностью | |
| EA201590562A1 (ru) | Бензамиды | |
| NZ720328A (en) | Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease | |
| HK1210699A1 (en) | Methods of administering and evaluating nitrogen scavenging drugs for the treatment of hepatic encephalopathy | |
| BR112013027486A2 (pt) | combinação de um inibidor de fosfatidilinositol-3-cinase (pi3k) e um inibidor de mtor | |
| JP2014513121A5 (enExample) | ||
| BR112016007238A2 (pt) | tienouracilcarboxamidas cíclicas e sua utilização | |
| BR112015001627A2 (pt) | composição farmacêutica, respectivos usos e método para diminuir a frequência de micção | |
| EA201491870A1 (ru) | Способ лечения гиперурикемии у больных подагрой с помощью галофената или галофеновой кислоты и противовоспалительного агента |